Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients	Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary central nervous system lymphoma	Active, not recruiting	Early phase 1	2026-06-04		NCT05651178

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Hrain Biotechnology Co., Ltd.	6
Second Affiliated Hospital of Nanchang University	90

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The Second Affiliated Hospital of Nanchang University	Nanchang	China	45